How to buy Baudax Bio stock | $0.903

Baudax Bio, Inc is a biotechnology business based in the US. Baudax Bio shares (BXRX) are listed on the NASDAQ and all prices are listed in US Dollars. Baudax Bio employs 57 staff and has a trailing 12-month revenue of around 0.00.

Baudax Bio stock price (NASDAQ: BXRX)

Use our graph to track the performance of BXRX stocks over time.

Baudax Bio shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$0.90
52-week range	$0.57 - $3.85
50-day moving average	$0.73
200-day moving average	$1.11
Wall St. target price	$3.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-3.59

Buy Baudax Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Baudax Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Baudax Bio, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Baudax Bio price performance over time

Historical closes compared with the close of $0.903 from 2021-05-28

1 week (2021-07-19)	N/A
1 month (2021-06-30)	18.71%
3 months (2021-04-30)	-20.09%
6 months (2021-01-26)	N/A

1 year (2020-07-26)	N/A
2 years (2019-07-26)	N/A
3 years (2018-07-26)	N/A
5 years (2016-07-26)	N/A

Baudax Bio financials

Revenue TTM	$691,000
Gross profit TTM	$-1,239,000
Return on assets TTM	-47.97%
Return on equity TTM	0%
Profit margin	0%
Book value	N/A
Market capitalisation	$52.3 million

TTM: trailing 12 months

Shorting Baudax Bio shares

There are currently 669,005 Baudax Bio shares held short by investors – that's known as Baudax Bio's "short interest". This figure is 2.2% up from 654,474 last month.

There are a few different ways that this level of interest in shorting Baudax Bio shares can be evaluated.

Baudax Bio's "short interest ratio" (SIR)

Baudax Bio's "short interest ratio" (SIR) is the quantity of Baudax Bio shares currently shorted divided by the average quantity of Baudax Bio shares traded daily (recently around 675762.62626263). Baudax Bio's SIR currently stands at 0.99. In other words for every 100,000 Baudax Bio shares traded daily on the market, roughly 990 shares are currently held short.

However Baudax Bio's short interest can also be evaluated against the total number of Baudax Bio shares, or, against the total number of tradable Baudax Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Baudax Bio's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Baudax Bio shares in existence, roughly 20 shares are currently held short) or 0.0292% of the tradable shares (for every 100,000 tradable Baudax Bio shares, roughly 29 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Baudax Bio.

Find out more about how you can short Baudax Bio stock.

Baudax Bio share dividends

We're not expecting Baudax Bio to pay a dividend over the next 12 months.

Baudax Bio overview

Baudax Bio, Inc. , a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial. The company was incorporated in 2019 and is based in Malvern, Pennsylvania. .

Frequently asked questions

What percentage of Baudax Bio is owned by insiders or institutions?
Currently 0.833% of Baudax Bio shares are held by insiders and 11.439% by institutions. How many people work for Baudax Bio?
Latest data suggests 57 work at Baudax Bio. When does the fiscal year end for Baudax Bio?
Baudax Bio's fiscal year ends in December. Where is Baudax Bio based?
Baudax Bio's address is: 490 Lapp Road, Malvern, PA, United States, 19355 What is Baudax Bio's ISIN number?
Baudax Bio's international securities identification number is: US07160F1075 What is Baudax Bio's CUSIP number?
Baudax Bio's Committee on Uniform Securities Identification Procedures number is: 07160F107